TPI Signs Macrolide API International Sales and Marketing Agreement

^{Published on 2011-06-15 18:40:26 - Market Wire}
 

TPI Signs Macrolide API International Sales and Marketing Agreement -- CHENGDU, China, June 15, 2011 /PRNewswire-Asia-FirstCall/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about TPI

CHENGDU, China, June 15, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: [ TPI ]), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that the signing of the sales and marketing agreement with RELATIONS International Ltd., a Bangladesh corporation that specializes in the API sales for its Azithromycin API product sales in the People’s Republic of Bangladesh. “The signing of the agreement demonstrates our effort in further developing our macrolide antibiotic API business internationally,” said Dr. Jiang, Chairman and CEO of TPI.

TPI forecasts $30 million domestic Azithromycin API revenue in China for the first year of operation from its Jiangchuan macrolide facility (JCM) that has an annual manufacturing capacity of 250 tons. The international sales revenue from macrolide API is expected to contribute additional revenue for TPI.

Currently the JCM's license for manufacturing Azithromycin API is active (H10970072). Additional information regarding JCM can be found at [ www.sfda.gov.cn ] (Chinese version).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: [ http://www.tianyinpharma.com ]

About RELATIONS International Ltd.

RELATIONS International Ltd. (RELATIONS), founded in 1978, incorporated in the People's Republic of Bangladesh, is located at Motijheel Commercial Area, Dhaka-1000, Bangladesh. It specializes in the sales of APIs and other medical/pharmaceutical products in Bangladesh. RELATIONS client base includes Sandoz - Austria, Spain, Italy, Germany&India, Sifavitor, ABC Farmaceutici, Solmag, Recordati, SIMS, Farchemia and Archimia etc of Italy, Kirsch, CF Budenheim, Peter-Greven of Germany, Viscose Closures of UK, Fuji Kasei, Kyowa Hakko and Kaneka of Japan. RELATIONS also established a number of business relations with Chinese manufactures including TPI.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

SOURCE Tianyin Pharmaceutical Co., Inc.

RELATED LINKS
[ http://www.tianyinpharma.com ]
[ http://www.sfda.gov.cn ]